Expertise in
15
conditions

Dr. Merry J. Markham

Florida Clinical Practice Association Inc
Gainesville, FL
Expertise in
15
conditions
Specialties:Hematology Oncology | Oncology
Accepting New Patients
Expertise in
15
conditions
OverviewInsuranceLocationsClinical Research

Overview

Merry Markham is a Hematologist Oncology specialist and an Oncologist in Gainesville, Florida. Dr. Markham is highly rated in 15 conditions, according to our data. Her top areas of expertise are Ovarian Cancer, Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, and Salpingo-Oophorectomy. Dr. Markham is currently accepting new patients.

Her clinical research consists of co-authoring 70 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in FL
Hospital Affiliations
Uf Health Shands Hospital
Languages Spoken
English
Gender
Female

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Health Options
  •  Humana
  •  Florida Blue

Locations

FLORIDA CLINICAL PRACTICE ASSOCIATION INC
1549 Gale Lemerand Dr, Gainesville, FL 32610
352-265-4357
Other Locations
FLORIDA CLINICAL PRACTICE ASSOCIATION INC
2001 Sw 13th St, Gi Clinic At Endoscopy Cent, Gainesville, FL 32608
352-265-8982
FLORIDA CLINICAL PRACTICE ASSOCIATION INC
1600 Sw Archer Rd, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Radiation, Drug, Other
Study Drugs: Cisplatin, Triapine
Study Phase: Phase 3
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 24, 2024
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Gemcitabine
Study Phase: Phase 1
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2024
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
A Phase II Study of the PARP Inhibitor Olaparib in Combination With the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Procedure, Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 16, 2024
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 16, 2024
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2023
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2023
Intervention Type: Drug
Study Drugs: Ribociclib, Letrozole
Study Phase: Phase 2
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
A Randomized, Controlled, Double-Arm, Double-Blind, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Combined With Placebo for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Drug
Study Drugs: VB-111, Paclitaxel
Study Phase: Phase 3
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials

70 Total Publications

Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms.
Journal: JCO precision oncology
Published: December 03, 2024
Similar Doctors
Expertise in
40
conditions
Dr. Nam H. Dang
Oncology | Hematology Oncology
Expertise in
40
conditions
Dr. Nam H. Dang
Oncology | Hematology Oncology
1600 Sw Archer Rd, 
Gainesville, FL 
 (0.4 mi)
352-273-7832
Languages Spoken:
English
See accepted insurances

Nam Dang is an Oncologist and a Hematologist Oncology provider in Gainesville, Florida. Dr. Dang is highly rated in 40 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Splenectomy, and Bone Marrow Aspiration.

Expertise in
14
conditions
Dr. Frederic J. Kaye
Hematology Oncology | Oncology
Expertise in
14
conditions
Dr. Frederic J. Kaye
Hematology Oncology | Oncology
1600 Sw Archer Rd, 
Gainesville, FL 
 (0.4 mi)
352-273-7760
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Frederic Kaye is a Hematologist Oncology specialist and an Oncologist in Gainesville, Florida. Dr. Kaye is highly rated in 14 conditions, according to our data. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Lung Adenocarcinoma, and Non-Small Cell Lung Cancer (NSCLC). Dr. Kaye is currently accepting new patients.

Expertise in
14
conditions
Dr. Coy D. Heldermon
Oncology | Hematology Oncology
Expertise in
14
conditions
Dr. Coy D. Heldermon
Oncology | Hematology Oncology

Florida Clinical Practice Association Inc

1600 Sw Archer Rd, 
Gainesville, FL 
 (0.4 mi)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Coy Heldermon is an Oncologist and a Hematologist Oncology provider in Gainesville, Florida. Dr. Heldermon is highly rated in 14 conditions, according to our data. His top areas of expertise are Breast Cancer, Gaucher Disease Type 2, Gaucher Disease Type 1, Gaucher Disease Type 3, and Tissue Biopsy. Dr. Heldermon is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile